-
Universal CD20 CAR-γδ T cell therapy has been granted Fast Track designation by the US FDA. What are the advantages of γδ T cells?
Time of Update: 2022-06-12
▲ Adicet’s γδ T cell-based cell therapy process (Image source: Adicet’s official website) In addition, Adicet has demonstrated that it can target by generating and validating high-affinity and high-specificity T cell receptor-like monoclonal antibodies (TCRLs) The intracellular proteome, these TCRLs against disease-specific antigens presented on the cell surface by MHC class I complexes, could be exploited to arm γδ T cells, as T cell linkers, and as ADCs .
-
FDA accepts Daprodustat's marketing application, and the treatment of renal anemia is expected to add another weapon!
Time of Update: 2022-06-12
S. Food and Drug Administration (FDA) has accepted the marketing application for Daprodustat for the treatment of anemia in patients with CKD, with a PDUFA date of February 1, 2023¹ .
-
Prof. Zhitao Ying: Research Progress of Antibody-Drug Conjugates in the Field of Hematology and Oncology 2021 China Oncology Congress
Time of Update: 2022-06-12
Chemotherapy can significantly improve the overall survival (OS) and progression-free survival (PFS) of patients; in addition, the 2021 ASH conference also announced another BV combined with CHEP regimen followed by BV consolidation in the treatment of patients with peripheral T-cell lymphoma (PTCL) As a result of efficacy, the patient objective response rate (ORR) was 91%, and the 18-month PFS rate and OS rate were 61% and 89%, respectively.
-
Blood: Detecting leukemia 16 years in advance?
Time of Update: 2022-06-12
The study, from a team from the Department of Immunology at Erasmus Medical Center in the Netherlands, analyzed the sequencing of blood samples from patients up to 22 years before diagnosis, and the results suggest that the preclinical stage of CLL may be longer than previously thought, even in patients with poor prognosis.
-
Professor Wu Depei on World AML Day: Interpreting the New Trend of R/R AML in Precision Targeted Therapy
Time of Update: 2022-06-12
Acute myeloid leukemia (AML) is the most common type of leukemia in adults and has historically had a high mortality rate . With the deepening of medical research, the treatment of AML has develop
-
【ITP changes because of you】Phase 2
Time of Update: 2022-06-10
"Clinical Practice Sharing Case 2 Basic Information: Gender: Female Age: 73-year-old initial platelet level: 1 × 109/L Hormone insufficiency: Hormone intolerance Table 2 Case 2 Follow-up and efficacy evaluation records Note: Eltrombopag is administered once a day (qd) .
-
Professor Zhang Mingming: Advances in Treatment of Peripheral T-Cell Lymphoma 2021 China Oncology Congress
Time of Update: 2022-06-10
Professor Zhang Mingming mentioned that in the past, the CHOP regimen for the treatment of diffuse large B-cell lymphoma was often used to treat PTCL, but the efficacy was poor, with poor overall survival (OS) and progression-free survival (PFS).
-
Courier Roche's potential 'first-in-class' bispecific therapy backed by EU CHMP, on track for first regulatory approval
Time of Update: 2022-06-09
▎WuXi AppTec Content Team Editor Today, Roche announced that the European Commission for Medicinal Products for Human Use (CHMP) of the European Union EMA recommended conditional approval of mosunetuzumab, a bispecific antibody targeting CD20 and CD3, for the treatment of relapsed or refractory follicles lymphoma .
-
Prof. Li Yuhua: Advances and Prospects of Drug Therapy for Indolent Lymphoma 2021 China Oncology Congress
Time of Update: 2022-06-08
Summary Professor Li Yuhua finally concluded that in the field of indolent lymphoma treatment, the chemotherapy regimen containing CD20 monoclonal antibody is the cornerstone of treatment, and the multi-target drug combination research carried out on this basis has significantly improved the remission rate and remission of relapsed and refractory patients.
-
Prof. Yan Xiaojing: Looking for the optimal treatment of DLBCL, I will search for the 2021 China Oncology Congress
Time of Update: 2022-06-08
Professor Yan Xiaojing The First Affiliated Hospital of China Medical University In the exploration of first-line treatment, researchers have gone through different eras, from improving the intensity and density of chemotherapy to optimizing CD20 antibodies, to exploring maintenance therapy and combination new drugs, but most of the attempts All were negative and unsuccessful .
-
Interview with Professor Zhou Shiyong for Lymphoma: Breaking the Dilemma of Relapse and Refractory Treatment
Time of Update: 2022-06-07
Multiple ongoing studies evaluating the efficacy of PI3K inhibitors in combination with targeted agents in R/R FL, including one exploring Umbralisib monotherapy and Umbralisib in combination with the novel anti-CD20 monoclonal antibody Ublituximab Phase I/Ib Promising data from the study showed an ORR of 44%, a CR rate of 22%, and a median DOR of 20.
-
Update of guidelines for the diagnosis and treatment of thrombocytopenia caused by tumor therapy 2022 CSCO guidelines
Time of Update: 2022-06-06
At the meeting, Professor Zhao Donglu from the Harbin Institute of Hematology and Oncology gave a detailed and wonderful explanation on the update points of the "Guidelines for the Diagnosis and Treatment of Thrombocytopenia Induced by Tumor Treatment" (2022 Edition) .
-
ORR 92.86%!
Time of Update: 2022-06-06
On this occasion, Yimaitong specially invited Professor Ma Jun from the Harbin Institute of Hematology and Oncology to interpret the updated highlights of the new "CSCO Lymphoma Diagnosis and Treatment Guidelines" and the application of sapalizumab .
-
The courier is a blockbuster!
Time of Update: 2022-06-05
▎WuXi AppTec Content Team Editor Today, Nkarta announced that the company's two major chimeric antigen receptor (CAR) natural killer (NK) cell candidate therapies, NKX101 and NKX019, are in two early-stage treatments for different blood cancer patient populations.
-
2022 CSCO Guidelines
Time of Update: 2022-06-05
Key Points As follows: >>>>Asparaginase-related complications Class IB evidence Level III recommendation: silent inactivation (replacement); thrombosis therapy (heparin); severe pancreatitis Professor Zhu Xiaofan mentioned that although the children were treated with asparaginase There is an allergic reaction during the process, but silent inactivation may occur.
-
Professor Ma Jun: Standard treatment helps clinical standardization, and takes stock of the key points of the 2022 CSCO follicular lymphoma guidelines update
Time of Update: 2022-06-05
In the preparatory process, the CSCO working group fully integrated the core authoritative research at home and abroad, strictly based on the evidence of evidence-based medicine, and updated the standards, methods and drugs of various types of tumor-related diagnosis and treatment in detail; Based on the actual situation of large clinical centers and primary medical institutions, the medical insurance policy and the availability of medical products are taken into consideration .
-
Industry heavyweight: Boshengji publishes long-term follow-up data of autologous CD7-CAR-T therapy in the treatment of r/r T-ALL/LBL
Time of Update: 2022-06-05
The results of the long-term follow-up data of the PA3-17 injection-related study are gratifying, indicating that the product candidate is expected to become a potential CAR-T cell monotherapy .
-
【ITP changes because of you】Phase 3
Time of Update: 2022-06-03
The content of this article is only for medical and health professionals. ITP disease background and treatment progress Primary immune thrombocytopenia (ITP) is a bleeding disorder caused by autoimm
-
Prof. Zhitao Ying: The first guideline for CAR-T treatment of hematological malignancies was released, helping to guide the application of CAR-T in China
Time of Update: 2022-06-03
Indications Evaluation of peripheral blood mononuclear cells before treatment Bridging therapy collection of peripheral blood mononuclear cells Lymphocyte depletion before chemotherapy Check the lymphocyte depletion chemotherapy regimen before reinfusion Confirmation of patient status before reinfusion Approaches ICANN's recommended treatment approach For multiple myeloma and acute B lymphocytic leukemia, although no corresponding CAR-T products have been approved in China, the corresponding clinical research is progressing smoothly, so BCMA-targeted CAR-T is recommended for previous recipients.
-
Prof. Zhu Jun: Innovative therapies keep up with the international frontiers, and take stock of the updated 2022 CSCO guidelines for diffuse large B-cell lymphoma
Time of Update: 2022-06-03
Coinciding with the release of the 2022 version of the CSCO Lymphoma Diagnosis and Treatment Guideline, Yimaitong sincerely invites Professor Zhu Jun from Peking University Cancer Hospital to interpret the updated highlights in the field of DLBCL in this guideline, and combine clinical practice to share the importance of these innovative therapies for the treatment of DLBCL.
